Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression
Status:
Terminated
Trial end date:
2018-04-05
Target enrollment:
Participant gender:
Summary
This study evaluated ADCT-502 in participants with Advanced Solid Tumors with HER2
Expression. Participants participated in a dose-escalation phase (Part 1) and were due to
participate in the dose expansion phase (Part 2). In Part 2, patients were due to receive the
dose level identified in Part 1, but the study was terminated prior to the beginning of Part
2.